Emerald BioStructures

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The firms achieved a second milestone in their drug discovery pact, which utilizes Emerald's X-ray crystallography platform.

Movers & Shakers

Premium

John Hunt, John McCall, John Mulligan, Lynn Silver

The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.

The firms are building on a collaboration from last year, under which they unraveled the first X-ray structure of a DNA aptamer bound to its protein target.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.